1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. T-CELL IMMUNOTHERAPY MARKET BY TYPE
5.1. Introduction
5.2. Chimeric antigen receptor (CAR)
5.3. T-cell receptor (TCR)
5.4. Tumor-infiltrating lymphocyte (TIL)
5.5. Others
6. T-CELL IMMUNOTHERAPY MARKET BY INDICATION
6.1. Introduction
6.2. Hematologic Malignancies
6.3. Solid Tumors
6.4. Autoimmune Diseases
6.5. Viral Infections
6.6. Others
7. T-CELL IMMUNOTHERAPY MARKET BY END-USERS
7.1. Introduction
7.2. Hospitals
7.3. Specialty Cell Therapy Centers
7.4. Ambulatory Surgical Centers
7.5. Research/Clinical Trial Sites
8. T-CELL IMMUNOTHERAPY MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Cellular Biomedicine Group
10.2. Autolus Novartis
10.3. Gilead Sciences, Inc
10.4. Adaptimmune Therapeutics
10.5. Cellectis
10.6. Bluebird bio
10.7. Immunocore
10.8. Innovative Cellular Therapeutics
10.9. Iovance Biotherapeutics
10.10. Celgene
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations LIST OF FIGURESLIST OF TABLES